Navigation Links
CrystalGenomics Announces Positive Results from Phase 2b Osteoarthritis Study of CG100649
Date:4/18/2012

649 and Celebrex treatment groups. Although a long-term cardiovascular safety profile could not be established by this short-term study, there were no indications that CG100649 had a negative impact on heart function, ECG profiles, or blood pressure.

Dr. William Schmidt, Vice President of Clinical Development, said, "The two higher doses of CG100649 used in this study complete the pre-planned Phase 2 dose-ranging phase for CG100649 and allow us to select a dose for the Phase 3 study that will be initiated later this year."

Dr. Joong Myung Cho, President & CEO of CrystalGenomics, stated, "This is an important milestone for CrystalGenomics and OA patients worldwide as we were successful in generating very exciting safety and efficacy data against Celebrex. The positive results from this Phase 2b study will strengthen CG100649's position of becoming the next generation NSAID for treating pain and other OA symptoms in patients with moderate to severe OA."

About CG100649
CG100649 is a first-in-class NSAID drug candidate that is a dual inhibitor of COX-2 and carbonic anhydrase (CA). CG100649's interaction with CA in red blood cells provides it with a novel 'tissue-specific' transport mechanism that is designed to deliver sustained levels of drug to inflamed tissues, while maintaining low systemic exposure. Its unique dual COX-2 and CA binding properties are designed to provide potentially superior safety to cardiovascular, renal, and gastrointestinal tissues compared to traditional NSAIDs or COX-2 inhibitor drugs.

About CrystalGenomics
CrystalGenomics, Inc. is a clinical stage biopharmaceutical company with drug discovery and development capabilities that is headquartered in Seoul, Korea, with a US presence for multi-national clinical management (CG Pharmaceuticals, Inc.) in Emeryville, California.  CrystalGenomics is publicly traded on the KOSDAQ exchange. CrystalGenomics is dedicated to the discovery and devel
'/>"/>

SOURCE CrystalGenomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
2. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
3. Pinnacle Biologics Inc. Announces Appointment of Bioprojet Pharma as Exclusive Distributor in Select European Countries
4. Stemline Therapeutics Announces Two Presentations of Direct Injection Synthetic Peptide Vaccine for Brain Cancer, Now Being Developed as SL-701, at the Annual Meeting of the American Association of Cancer Research (AACR)
5. Akorn, Inc. Announces First Quarter 2012 Earnings Release and Conference Call Information
6. Tengion Announces IND Filing for Neo-Kidney Augment Expected During First Half of 2013
7. ConvaTec Healthcare Announces 2011 Year-end Earnings Call
8. The Galien Foundation Announces Prix Galien USA Awards Committee, Chaired by Dr. P. Roy Vagelos
9. Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer
10. Sangamo BioSciences Announces Presentation at the Future Leaders in the Biotech Industry Conference
11. Gamma Pharmaceuticals, Inc. Announces Distribution Agreement for New York Tri-state Area and Purchase Order for Gamma Energy GEL™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014  CVS Caremark Corporation (NYSE: ... on Tuesday, August 5, 2014, at 8:30 a.m. (EDT) ... 2014 financial results. An audio webcast of ... Investor Relations portion of the CVS Caremark website for ... http://info.cvscaremark.com/investors . This webcast will be archived and available ...
(Date:7/25/2014)... N.J. , July 25, 2014  Acsis ... brand protection and serialization solutions, has recently posted ... that addresses current and future needs for ... for the old supply chain model no longer ... in technology, including the growth of mobile technology, ...
(Date:7/25/2014)... , July 25, 2014 Research ... "Global Ophthalmic Diagnostic Devices Market 2014-2018" report ... About Ophthalmic Diagnostic Device ... used to identify a defect or deficiency in the ... with ophthalmic disorders such as presbyopia, cataracts, glaucoma, retinal ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... Mylan Inc. (Nasdaq: www.mylan.com . ... release includes statements that constitute "forward-looking statements." These statements ... the Private Securities Litigation Reform Act of 1995. Because ... results may differ materially from those expressed or implied ...
... 6 Endo Pharmaceuticals (Nasdaq: ENDP ) today ... Specialty Pharmaceuticals Conference on Thursday, August 12, 2010 , at 8:00 ... Endo, will review the company,s products and development programs. , ... The presentation will be webcast live and can ...
Cached Medicine Technology:Endo to Present at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference 2
(Date:7/25/2014)... Ticket Down is a reliable source for cheap ... California Memorial Stadium. With the post-World Cup emotions still rolling ... the 2014 Guinness International Champions Cup have brought eight of ... representing La Liga, English Premier League, Serie A, and Superleague ... players from around the world to 12 American cities and ...
(Date:7/25/2014)... 25, 2014 On July 22, ... Media client and the nation’s number one provider ... handbooks, announced their partnership with TransAct Merchant Solutions’ ... registered ISO/MSP of Chase Paymentech Solutions, LLC, which ... industry. Companies that are members of TransAct’s National ...
(Date:7/25/2014)... July 25, 2014 Hastings and ... discount attorney’s fees with regard to personal injury claims, ... a wide range of legal services for those that ... of another individual or corporation. Free initial consultation services ... validity of a potential personal injury claim . ...
(Date:7/25/2014)... especially men, may be at higher risk for type 2 ... study suggests. Also at special risk are shift workers ... around at various times of the day. The findings ... Manevitz, a clinical psychiatrist at Lenox Hill Hospital in New ... disrupts many key body chemicals, creating a ripple effect that ...
(Date:7/25/2014)... An experimental anti-inflammatory drug can protect vulnerable neurons ... of Parkinson,s disease, researchers at Emory University School ... published in the Journal of Parkinson,s Disease ... called XPro1595, can reach the brain at sufficient ... subcutaneous injection, like an insulin shot. Previous studies ...
Breaking Medicine News(10 mins):Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2
... CA Scientists at the Salk Institute for Biological Studies have ... protein in cells. The protein, p53, can cause cells to ... signs of DNA damage, and it is responsible for much ... or DNA-damaging drugs such as the ones commonly used for ...
... patients with certain other health problems have higher mortality ... study published online June 30 in the Journal ... problems, or ,comorbidities, include heart attack and other heart-related ... Previous studies have shown that comorbidities as a group ...
... Today the International and American Associations for Dental Research announced ... ) has increased its Five-Year Scientific Impact Factor (SIF) from ... category, the Journal ranked #1 in Article Influence. This news ... rankings, published by the Journal Citation Reports (JCR). This latest ...
... researchers from Boston University School of Medicine (BUSM) and ... high rate of thyroid function testing in pregnant women. ... the Journal of Clinical Endocrinology & Metabolism , ... testing on pregnant women, approximately 80 percent of cases ...
... in young adult mice that a lone brain stem cell is ... neurons and glia important types of brain cells but ... stem cells. A report on their study appears June 24 ... brain has the capacity to generate both neurons, which send and ...
... Reinberg HealthDay Reporter , THURSDAY, June 30 (HealthDay ... up in emergency rooms for drinking-related injuries doubles over the ... and 4, drinking sends a daily average of nearly 1,000 ... the ER for problems related to alcohol use, according to ...
Cached Medicine News:Health News:The genome guardian's dimmer switch: Regulating p53 is a matter of life or death 2Health News:The genome guardian's dimmer switch: Regulating p53 is a matter of life or death 3Health News:Worse outcomes for older breast cancer patients with other health problems 2Health News:Journal of Dental Research increases its scientific impact factor 2Health News:BMC conducts high rates of thyroid testing in pregnant women, study finds 2Health News:Nervous system stem cells can replace themselves, give rise to variety of cell types, even amplify 2Health News:July 4 Weekend Dangerous for Underage Boys Who Drink: Report 2
... breakthrough continuous low-flow nebulizer performance. Patented ... technology allows for optimal medication and ... Heliox). OMNI~NEB takes on severe asthma, ... and critical care situations. Configure with ...
... developing diverse medical products for ... medical-surgical products have earned an ... and customer satisfaction. Graham-Fields internationally ... line of diagnostic instruments, Grafco® ...
... metered dose inhalers., ,ACE ensures prompt, ... canisters. Its versatile design allows it to ... conjunction with an endotracheal airway or resuscitation ... may also be used in conjunction with ...
Kit Nebulizer Small Volume Medication W/Pediatric Mask Mouthpiece 7FT O 2 Tubing...
Medicine Products: